UC SAN FRANCISCO and Berkeley Lights Inc. formed a collaboration that gives UCSF researchers access to Berkeley Lights’ opto-nanofluidic biosystems, including single-cell genomic profiling of pre-annotated tissue samples, the development of precision diagnostics, and point-of-care therapies. Through the collaboration, UCSF researchers will study various cancer types to better understand the characterization and functionality of cell... […]
TUFTS MEDICAL CENTER and New England Cancer Specialists formed a clinical affiliation to expand patients’ access to care, clinical trials, and survivorship resources. NECS is the largest provider of cancer services in Maine, with nearly 45,000 patient visits in 2015 at locations in Scarborough, Brunswick and Kennebunk. Through the affiliation agreement, Tufts MC will be... […]
BAYLOR COLLEGE OF MEDICINE and Baylor Scott & White Health have entered into an agreement to expand biomedical research in North and Central Texas. The largest not-for-profit health care system in Texas, Baylor Scott & White Health was born from the 2013 merger of Baylor Health Care System and Scott & White Healthcare. A search... […]
NanoString Technologies Inc. entered into a collaboration agreement with Merck, through a subsidiary, to develop and commercialize a novel diagnostic assay to predict response to Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy. Under the terms of the collaboration agreement, NanoString will be responsible for seeking regulatory approval for and commercialization of the diagnostic test. NanoString will be... […]
Merck KGaA, Pfizer and Verastem entered into an agreement to evaluate avelumab, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, in combination with Verastem’s VS-6063, an investigational focal adhesion kinase inhibitor, in patients with advanced ovarian cancer. Avelumab is currently under clinical investigation across a broad range of tumor types. The phase I/Ib clinical trial... […]
FDA and the European Medicines Agency have both granted Orphan Drug Designation to FLAG-003 for the treatment of glioma, sponsored by FLAG Therapeutics. Orphan status is granted by the FDA to promote the development of products that demonstrate promise for the treatment of rare diseases, those which affect fewer than 200,000 Americans annually. Orphan drug... […]
The European Medicines Agency granted an Orphan Drug Designation to venetoclax, an investigational, oral B-cell lymphoma-2 inhibitor, for the treatment of acute myeloid leukemia. Venetoclax is being developed by AbbVie in partnership with Genentech and Roche. The EMA previously granted Orphan Drug Designation to venetoclax for the treatment of chronic lymphocytic leukemia. Orphan Designation is... […]
FDA granted orphan drug designation to the WT1 cancer vaccine developed by SELLAS Life Sciences Group for the treatment of patients with malignant pleural mesothelioma. SELLAS recently reported positive results of a phase II trial of its WT1 vaccine in MPM patients, showing that overall survival improved and progression-free survival doubled. Based on these findings,... […]
Health Canada approved Opdivo injection (nivolumab), the first and only immuno-oncology therapy approved in Canada for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with progression on or after platinum-based chemotherapy. The approval was made under the Health Canada Priority Review process, after having met the criteria of substantial... […]
FDA approved Imbruvica (ibrutinib) as a first-line treatment for patients with chronic lymphocytic leukemia.
